EYPTEyePoint, Inc.
Laboratory Analytical Instruments
- Revenue
- $31M
- 28% YoY
- Operating margin
- -776.0%
- 130% YoY
- EBITDA
- −$241M
- 67% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$80M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired89% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $37M | $41M | $46M | $43M | $31M | 28% |
| Operating income | −$55M | −$100M | −$75M | −$146M | −$243M | 67% |
| Net income | −$58M | −$102M | −$71M | −$131M | −$232M | 77% |
| Operating cash flow | −$50M | −$65M | $2M | −$126M | −$240M | 90% |
| Capex | $156K | $2M | $3M | $4M | $3M | 19% |
| Stock-based comp | $7M | $14M | $12M | $37M | $28M | 24% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $14M | 522 | — |
| FY2024 | — | — | 213 | — |
| FY2023 | — | — | 660 | — |